Patents Examined by Zachary Skelding
-
Patent number: 9670285Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: December 15, 2015Date of Patent: June 6, 2017Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULARInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 9663576Abstract: Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-B cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. In other embodiments, optimal dosages of therapeutic antibody may be selected by monitoring the degree of trogocytosis induced by anti-B cell antibodies.Type: GrantFiled: September 7, 2016Date of Patent: May 30, 2017Assignee: Immunomedics, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen, Edmund A. Rossi
-
Patent number: 9663763Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.Type: GrantFiled: January 22, 2016Date of Patent: May 30, 2017Assignee: THE TRUSTEES OF DARTMOUTH COLLEGEInventor: Charles L. Sentman
-
Patent number: 9649339Abstract: LAT (Linker for Activation of T-cells) is a protein involved in signaling through the T-cell receptor (TCR). The invention provides a LAT protein including mutations at ubiquitylation sites that result in an increase in stability of LAT in stimulated and unstimulated cells, and enhanced signaling through the TCR. The invention further provides use for a LAT protein including mutations at ubiquitylation sites for therapeutic and laboratory methods.Type: GrantFiled: July 11, 2014Date of Patent: May 16, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Lawrence E. Samelson, Lakshmi Balagopalan
-
Patent number: 9650445Abstract: The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell.Type: GrantFiled: October 21, 2015Date of Patent: May 16, 2017Assignee: The University of BirminghamInventors: Mark Cobbold, David Millar
-
Patent number: 9644035Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: GrantFiled: March 14, 2013Date of Patent: May 9, 2017Assignees: Omeros Corporation, University of LeicesterInventors: Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
-
Patent number: 9629909Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: June 18, 2013Date of Patent: April 25, 2017Assignee: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 9631014Abstract: Disclosed is a method of diagnosing graft-versus-host disease, comprising measuring the level of CCL8 protein in a sample obtained from a subject as an indicator for the diagnosis or course of graft-versus-host disease. Also a diagnostic reagent for graft-versus-host disease comprising an anti-CCL8 antibody is disclosed. The method of the present invention enables diagnosis of the onset of graft-versus-host disease and monitoring of the progress, in particular, differential diagnosis between graft-versus-host disease and an infectious disease. The present invention also provides a method for treating graft-versus-host disease utilizing the anti-CCL8 antibody.Type: GrantFiled: April 3, 2014Date of Patent: April 25, 2017Assignee: SAPPORO MEDICAL UNIVERSITYInventors: Tsukasa Hori, Yasuo Kokai, Yasuyoshi Naishiro, Hiroyuki Tsutsumi, Kohzoh Imai
-
Patent number: 9624292Abstract: The present invention relates to a single chain antigen recognizing construct (scARC), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous ARC chains. The invention further discloses a method for the design of a novel structurally stabilized scARC, the method being based on the visual inspection of the crystal structure of the underlying scARC and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure. Furthermore, the invention discloses a method for the production of a cell which expresses the scARC of the invention. Also described are nucleic acids encoding an inventive scARC, as well as DNA and RNA constructs that allow for the expression of the inventive scARC.Type: GrantFiled: March 26, 2012Date of Patent: April 18, 2017Assignee: Universitätsmedizin Der Johannes Gutenberg-Universität MainzInventors: Ralf-Holger Voss, Shao-An Xue, Matthias Theobald, Hans Stauss
-
Patent number: 9587021Abstract: CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey) are presented. Uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions are presented.Type: GrantFiled: May 16, 2012Date of Patent: March 7, 2017Assignee: MacroGenics, Inc.Inventors: Ling Huang, Leslie S. Johnson
-
Patent number: 9586997Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.Type: GrantFiled: September 19, 2011Date of Patent: March 7, 2017Assignees: BioNtech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbHInventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
-
Patent number: 9580502Abstract: An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human TNF. Such binding disrupts assembly of the monomer into bioactive trimeric human sTNF. A pharmaceutical composition contains one or more antibodies or ligands: (a) an antibody or ligand that specifically binds the TNF monomer-specific epitope having the sequence PSDKPVAH or PSDKPVAHV, amino acids 8-15 or 8-16 of SEQ ID NO: 1; and (b) an antibody or ligand that specifically binds the TNF monomer-specific epitope having the sequence EPIYLGGVF, amino acids 116 to 124 of SEQ ID NO: 1. A combination of antibodies or ligands that bind or are reactive with (a) and/or (b) are useful in methods for treating a subject having a disease (e.g., rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis, atherosclerosis, metabolic syndrome, Alzheimer's Disease, HIV, Type II diabetes) mediated by human TNF.Type: GrantFiled: June 8, 2016Date of Patent: February 28, 2017Assignee: Thymon, LLCInventor: Gideon Goldstein
-
Patent number: 9567566Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.Type: GrantFiled: June 26, 2012Date of Patent: February 14, 2017Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: De Yang, Joost J. Oppenheim, Michael Bustin
-
Patent number: 9567387Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.Type: GrantFiled: March 27, 2013Date of Patent: February 14, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Qiong J. Wang, Kenichi Hanada, James C. Yang
-
Patent number: 9562090Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: February 11, 2013Date of Patent: February 7, 2017Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Carolyn Enever, Ian Tomlinson
-
Patent number: 9550831Abstract: The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.Type: GrantFiled: September 13, 2010Date of Patent: January 24, 2017Assignee: BIOTEST AGInventors: Silke Aigner, Matthias Germer, Frank Osterroth, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken, Gregor Schulz
-
Patent number: 9546210Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: GrantFiled: September 21, 2010Date of Patent: January 17, 2017Assignee: Research Development FoundationInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Patent number: 9546212Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.Type: GrantFiled: June 10, 2016Date of Patent: January 17, 2017Assignee: AbbVie Biotechnology Ltd.Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
-
Patent number: 9534053Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.Type: GrantFiled: March 5, 2014Date of Patent: January 3, 2017Assignees: Amgen Inc., E.R. Squibb & Sons, L.L.C.Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
-
Patent number: 9527916Abstract: The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim 1 which may comprise: an antibody heavy chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 5, 6 and 7, or a variant of any of said sequences; and/or an antibody light chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 8, 9 and 10, or a variant of any of said sequences.Type: GrantFiled: December 19, 2012Date of Patent: December 27, 2016Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Winfried Robert Mulder, Jannetje Geertruida Borst, Aartje Maria Elizabeth Veraar, Paul Maria Frederikus Vink